Chroma Dex Corp. CDXC
We take great care to ensure that the data presented and summarized in this overview for ChromaDex Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CDXC
View all-
Vanguard Group Inc Valley Forge, PA3.43MShares$23.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.12MShares$20.9 Million0.0% of portfolio
-
Tieton Capital Management, LLC Yakima, WA2.96MShares$19.9 Million5.59% of portfolio
-
Iconiq Capital, LLC San Francisco, CA1.3MShares$8.71 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA1.15MShares$7.73 Million0.0% of portfolio
-
State Street Corp Boston, MA618KShares$4.15 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny424KShares$2.85 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL378KShares$2.54 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY332KShares$2.23 Million0.0% of portfolio
-
Royal Bank Of Canada Toronto, A6201KShares$1.35 Million0.0% of portfolio
Latest Institutional Activity in CDXC
Top Purchases
Top Sells
About CDXC
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Insider Transactions at CDXC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 13
2024
|
Frank L Jaksch Jr Director |
SELL
Open market or private sale
|
Direct |
37,161
-13.21%
|
$222,966
$6.19 P/Share
|
Dec 13
2024
|
Frank L Jaksch Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,001
+15.09%
|
$150,003
$3.66 P/Share
|
Nov 22
2024
|
Ozan Pamir Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,907
+50.0%
|
$20,349
$7.36 P/Share
|
Aug 23
2024
|
Kristin Patrick Director |
SELL
Open market or private sale
|
Direct |
23,000
-100.0%
|
$69,000
$3.57 P/Share
|
Aug 23
2024
|
Kristin Patrick Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,000
+48.26%
|
$23,000
$1.66 P/Share
|
Aug 20
2024
|
Hoi Shuen Solina Holly Chau |
BUY
Open market or private purchase
|
Indirect |
11,408,715
+37.16%
|
-
|
Aug 20
2024
|
Ka Shing Li |
SELL
Open market or private sale
|
Indirect |
11,408,715
-100.0%
|
-
|
Dec 01
2023
|
Brianna Gerber Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+15.42%
|
$5,000
$1.41 P/Share
|
Sep 06
2023
|
Champion River Ventures LTD Director |
BUY
Open market or private purchase
|
Indirect |
3,467,778
+23.31%
|
-
|
Aug 12
2023
|
Brianna Gerber Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,436
+50.0%
|
-
|
Jun 12
2023
|
Frank L Jaksch Jr Director |
BUY
Open market or private purchase
|
Direct |
7,000
+2.94%
|
$7,000
$1.69 P/Share
|
May 31
2023
|
Robert N Fried Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
7,000
+6.86%
|
$7,000
$1.42 P/Share
|
May 25
2023
|
Steven D Rubin Director |
BUY
Open market or private purchase
|
Direct |
7,000
+50.0%
|
$7,000
$1.46 P/Share
|
Sep 30
2022
|
Robert N Fried Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
80,000
+7.6%
|
$80,000
$1.25 P/Share
|
Sep 30
2022
|
Hoi Shuen Solina Holly Chau |
BUY
Open market or private purchase
|
Indirect |
960,000
+10.85%
|
$960,000
$1.25 P/Share
|
Jun 16
2022
|
Hoi Shuen Solina Holly Chau |
BUY
Open market or private purchase
|
Indirect |
60,037
+0.86%
|
$60,037
$1.66 P/Share
|
Mar 16
2022
|
Robert N Fried Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
25,000
+22.12%
|
$50,000
$2.16 P/Share
|
May 13
2021
|
Robert N Fried Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
10,000
+13.7%
|
$60,000
$6.65 P/Share
|
Mar 16
2021
|
Stephen A Block Director |
SELL
Open market or private sale
|
Direct |
20,000
-54.55%
|
$260,000
$13.17 P/Share
|
Mar 16
2021
|
Stephen A Block Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+35.29%
|
$40,000
$2.6 P/Share
|
Last 12 Months Summary
Open market or private purchase | 11.4M shares |
---|---|
Exercise of conversion of derivative security | 73K shares |
Open market or private sale | 11.5M shares |
---|